Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
IL

NASDAQ · ILMN

Illumina, Inc.

Healthcare · Medical - Diagnostics & Research

$235.99

Down-$54.07 (-18.64%)

Updated Oct 31, 2026, 6:37 PM

SID Score

6.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
20.84B
P/E ratio
30.27
Dividend yield
0.00%
52-week range
$94.00 – $309.35
Volume
5.39M
Avg. volume
1.79M

Price performance · ILMN

ILMN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ILMN closed at $235.99 after 21 trading sessions, down 13.57% for the selected period.

Last close
$235.99
Period change
-13.57%
Period low
$235.99
Period high
$293.69
Daily close
View OHLC price history
ILMN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$255.765$256.09$231.18$235.995.39M
Oct 29, 2026$286.05$293.17$283.00$290.062.04M
Oct 28, 2026$278.04$294.205$277.20$288.792.24M
Oct 27, 2026$269.42$282.18$266.20$279.471.78M
Oct 26, 2026$269.69$274.00$267.29$271.041.33M
Oct 23, 2026$264.42$271.64$264.42$269.421.26M
Oct 22, 2026$281.42$283.55$257.3101$269.402.22M
Oct 21, 2026$267.35$286.40$263.28$282.862.27M
Oct 20, 2026$264.13$271.43$260.15$267.931.58M
Oct 19, 2026$268.93$270.94$260.24$262.661.9M
Oct 16, 2026$267.49$272.005$259.255$262.542.49M
Oct 15, 2026$267.24$275.49$257.14$267.932.99M
Oct 14, 2026$269.19$276.55$267.23$271.762.12M
Oct 13, 2026$276.58$276.85$267.27$271.1751.9M
Oct 12, 2026$277.60$278.00$268.52$276.671.64M
Oct 9, 2026$268.21$278.59$265.25$278.171.9M
Oct 8, 2026$263.69$266.135$254.00$264.573.17M
Oct 7, 2026$271.21$276.20$260.45$267.762.95M
Oct 6, 2026$301.58$309.345$271.5519$273.544.38M
Oct 5, 2026$273.00$296.25$271.61$293.694.22M
Oct 2, 2026$265.91$274.97$265.39$273.042.84M

Latest ILMN news

The latest Smart Investors Daily articles mentioning ILMN.

Stock researchCompany · Overview

ILMN research

Overview

Company profile and research snapshot.

Company profile

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$115.25
Implied upside
—
Analysts
28
ILMN recent ratings
DateFirmRatingTarget
Oct 30, 2026Evercore ISI GroupOutperform—
Oct 19, 2026Canaccord GenuityHold—
Oct 13, 2026TD CowenHold—
Oct 7, 2026BarclaysUnderweight—
Oct 5, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

How Investors May Respond To Illumina (ILMN) BioInsight AI Rollout

Illumina has rolled out three early access capabilities on its BioInsight Platform: Workflow Orchestrator, DRAGEN Ultra with dnaAI, and Learning Cohorts, to help researchers connect sequencing, analysis, and large scale genomic datasets more efficiently. The focus on AI driven variant prioritization and cohort level analysis indicates that Illumina is placing more emphasis on software and data workflows rather than relying only on instruments and consumables. The key question now is how...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By